Isoprostanes, biomarkers of lipid peroxidation in humans. Part 3: Biomarkers and mediators in vascular physiology and disease;Les isoprostanes, biomarqueurs de peroxydation lipidique chez l'homme. Partie 3: Biomarqueurs et médiateurs en physiologie et pathologie vasculaire

Pathologie Biologie

Volumn 53, Issue 6, 2005, Pages 364-368

  Cracowski, J L ^a   Berdeaux, O ^b   Durand, T ^c  

^a UNIV GRENOBLE ALPES   (France)

^b CEMAGREF   (France)

^c CNRS   (France)

Author keywords

Atherosclerosis; Hypertension; Ischaemia; Isoprostane; Lipid peroxidation; Vasoconstriction

Indexed keywords

6,8 DIFLUORO 1,2,3,4 TETRAHYDRO 9 (4 METHYLSULFONYLBENZYL)CARBAZOLE 1 ACETIC ACID; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; BIOLOGICAL MARKER; ISOPROSTANE DERIVATIVE; S 18886; THROMBOXANE RECEPTOR; THROMBOXANE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CELL ADHESION; CORRELATION ANALYSIS; DISEASE SEVERITY; ENDOTHELIUM CELL; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATION; ISCHEMIA; LIPID PEROXIDATION; MEDIATOR; MITOGENESIS; MONOCYTE; NONHUMAN; PROGNOSIS; PULMONARY HYPERTENSION; REPERFUSION INJURY; REVIEW; SMOOTH MUSCLE FIBER; STIMULATION; VASCULAR DISEASE; VASOCONSTRICTION;

EID: 21744445088     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2004.10.007     Document Type: Short Survey

References (46)

1. L.J. Roberts, and J.D. Morrow Measurement of F2-isoprostanes as an index of oxidative stress in vivo Free Radic. Biol. Med. 28 2000 505 513
2. J.L. Cracowski, P. Devillier, T. Durand, F. Stanke-Labesque, and G. Bessard Vascular biology of the isoprostanes J. Vasc. Res. 38 2001 93 103
3. S.M. Miggin, and B.T. Kinsella Thromboxane A2 receptor mediated activation of the mitogen activated protein kinase cascades in human uterine smooth muscle cells Biochim. Biophys. Acta 1539 2001 147 162
4. B.T. Kinsella Thromboxane A2 signalling in humans: a 'Tail' of two receptors Biochem. Soc. Trans. 29 2001 641 654
5. P. McNamara, J.A. Lawson, J. Rokach, and G.A. FitzGerald Isoprostane activation of the nuclear hormone receptor PPAR Adv. Exp. Med. Biol. 507 2002 351 355
6. S. Marlìre, J.L. Cracowski, T. Durand, O. Chavanon, J. Bessard, and A. Guy The 5- series F2-isoprostanes possess no vasomotor effects in the rat thoracic aorta, the human internal mammary artery and the human saphenous vein Br. J. Pharmacol. 135 2002 1276 1280
7. X. Hou, L.J. Roberts 2nd, F. Gobeil Jr., D. Taber, K. Kanai, and D. Abran Isomer-specific contractile effects of a series of synthetic f2-isoprostanes on retinal and cerebral microvasculature Free Radic. Biol. Med. 36 2004 163 172
8. L.J. Janssen, and T. Tazzeo Involvement of TP and EP3 receptors in vasoconstrictor responses to isoprostanes in pulmonary vasculature J. Pharmacol. Exp. Ther. 301 2002 1060 1066
9. J.L. Cracowski, P. Devillier, O. Chavanon, F.A. Sietchiping-Nzepa, F. Stanke-Labesque, and G. Bessard Isoprostaglandin E2 type III (8-iso-prostaglandin E2) evoked contractions in human internal mammary artery Life Sci. 68 2001 2405 2413
10. J.D. Morrow, J.A. Awad, A. Wu, W.E. Zackert, V.C. Daniel, and L.J. Roberts 2nd Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) in vivo J. Biol. Chem. 271 1996 23185 23190
11. C.J. Brame, O. Boutaud, S.S. Davies, T. Yang, J.A. Oates, and D. Roden Modification of proteins by isoketal-containing oxidized phospholipids J. Biol. Chem. 279 2004 13447 13451
12. J.H. Cranshaw, T.W. Evans, and J.A. Mitchell Characterization of the effects of isoprostanes on platelet aggregation in human whole blood Br. J. Pharmacol. 132 2001 1699 1706
13. L. Fontana, C. Giagulli, P. Minuz, A. Lechi, and C. Laudanna 8-Iso-PGF2a induces beta 2-integrin-mediated rapid adhesion of human polymorphonuclear neutrophils: a link between oxidative stress and ischemia/reperfusion injury Arterioscler. Thromb. Vasc. Biol. 21 2001 55 60
14. J.P. Fessel, N.A. Porter, K.P. Moore, J.R. Sheller, and L.J. Roberts 2nd Discovery of lipid peroxidation products formed in vivo with a substituted tetrahydrofuran ring (isofurans) that are favored by increased oxygen tension Proc. Natl. Acad. Sci. U S A 99 2002 16713 16718
15. J.D. Morrow, B. Frei, A.W. Longmire, J.M. Gaziano, S.M. Lynch, and Y. Shyr Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers N. Engl. J. Med. 332 1995 1198 1203
16. Z. Mallat, I. Philip, M. Lebret, D. Chatel, J. Maclouf, and A. Tedgui Elevated levels of 8-iso-prostaglandin F2a in pericardial fluid of patients with heart failure: a potential role for in vivo oxidant stress in ventricular dilatation and progression to heart failure Circulation 97 1998 1536 1539
17. J.L. Cracowski, F. Tremel, C. Marpeau, J.P. Baguet, F. Stanke-Labesque, and J.M. Mallion Increased formation of F2-isoprostanes in patients with severe heart failure Heart 84 2000 439 440
18. M. Nonaka-Sarukawa, K. Yamamoto, H. Aoki, H. Takano, T. Katsuki, and U. Ikeda Increased urinary isoprostane excretion in patients with non-ischemic congestive heart failure: a marker of oxidative stress Heart 2003
19. J.L. Cracowski, C. Cracowski, G. Bessard, J.L. Pepin, J. Bessard, and C. Schwebel Increased lipid peroxidation in patients with pulmonary hypertension Am. J. Respir. Crit. Care Med. 164 2001 1038 1042
20. E. Schwedhelm, A. Bartling, H. Lenzen, D. Tsikas, R. Maas, and J. Brummer Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study Circulation 109 2004 843 848
21. J. Cracowski, A. Yaici, O. Sitbon, M. Reynaud-Gaubert, J. Renversez, and C. Pison Evaluation pronostique de biomarqueurs dans l'hypertension art́rielle pulmonaire. Justification et plan exṕrimental Rev. Mal. Resp. 2004 in press
22. L. Iuliano, D. Pratico, C. Greco, E. Mangieri, G. Scibilia, and G.A. FitzGerald Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA J. Am. Coll. Cardiol. 37 2001 76 80
23. A.J. Cayatte, Y. Du, J. Oliver-Krasinski, G. Lavielle, T.J. Verbeuren, and R.A. Cohen The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice : evidence that eicosanoids other than thromboxane contribute to atherosclerosis Arterioscler. Thromb. Vasc. Biol. 20 2000 1724 1728
24. D. Pratico, R.K. Tangirala, D.J. Rader, J. Rokach, and G.A. FitzGerald Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice Nat. Med. 4 1998 1189 1192
25. L. Belhassen, G. Pelle, J.L. Dubois-Rande, and S. Adnot Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin J. Am. Coll. Cardiol. 41 2003 1198 1204
26. D. Pratico, Y. Cheng, and G.A. FitzGerald TP or not TP: primary mediators in a close runoff? Arterioscler. Thromb. Vasc. Biol. 20 2000 1695 1698
27. D. Pratico, D. Ferro, L. Iuliano, J. Rokach, F. Conti, and G. Valesini Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation Blood 93 1999 3401 3407
28. M.E. Martinuzzo, R.R. Forastiero, L. Kordich, and L.O. Carreras Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies Br. J. Haematol. 114 2001 845 851
29. F. Van Kooten, G. Ciabattoni, C. Patrono, D.W. Dipple, and P.J. Koudstaal Platelet activation and lipid peroxidation in patients with acute ischemic stroke Stroke 28 1997 1557 1563
30. T.F. Lindsay, X.P. Luo, D.C. Lehotay, B.B. Rubin, M. Anderson, and P.M. Walker Ruptured abdominal aortic aneurysm, a "two-hit" ischemia/reperfusion injury: evidence from an analysis of oxidative products J. Vasc. Surg. 30 1999 219 228
31. N. Delanty, M.P. Reilly, D. Pratico, J.A. Lawson, J.F. McCarthy, and A.E. Wood 8-epi PGF2a generation during coronary reperfusion Circulation 95 1997 2492 2499
32. M.P. Reilly, N. Delanty, L. Roy, J. Rokach, P.O. Callaghan, and P. Crean Increased formation of the isoprostanes IPF2a-I and 8-epi-prostaglandin F2a in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans Circulation 96 1997 3314 3320
33. L. Iuliano, F. Micheletta, M. Maranghi, G. Frati, U. Diczfalusy, and F. Violi Bioavailability of vitamin E as function of food intake in healthy subjects: effects on plasma peroxide-scavenging activity and cholesterol-oxidation products Arterioscler Thromb. Vasc. Biol. 21 2001 E34 E37
34. P. Rossi, A. Riutta, P. Kuukasjarvi, T. Vehmas, I. Mucha, and J.P. Salenius Revascularization decreases 8-isoprostaglandin F2alpha excretion in chronic lower limb ischemia Prostaglandins Leukot Essent Fatty Acids 71 2004 97 101
35. D. Pratico, L. Iuliano, A. Mauriello, L. Spagnoli, J.A. Lawson, and J. Maclouf Localization of distinct F2-isoprostanes in human atherosclerotic lesions J. Clin. Invest. 100 1997 2028 2034
36. J.L. Cracowski, J.P. Baguet, O. Ormezzano, J. Bessard, F. Stanke-Labesque, and G. Bessard Lipid peroxidation is not increased in patients with untreated mild-to-moderate hypertension Hypertension 41 2003 286 288
37. P. Minuz, P. Patrignani, S. Gaino, M. Degan, L. Menapace, and R. Tommasoli Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease Circulation 106 2002 2800 2805
38. N.C. Ward, J.M. Hodgson, I.B. Puddey, T.A. Mori, L.J. Beilin, and K.D. Croft Oxidative stress in human hypertension: association with antihypertensive treatment, gender, nutrition, and lifestyle Free Radic. Biol. Med. 36 2004 226 232
39. J. Helmersson, P. Mattsson, and S. Basu Prostaglandin F2a metabolite and F2-isoprostane excretion in migraine Clin. Sci. 102 2002 39 43
40. J.L. Cracowski, P.H. Carpentier, B. Imbert, S. Cachot, F. Stanke-Labesque, and J. Bessard Increased urinary F2-isoprostanes in systemic sclerosis but not in primary Raynaud's phenomenon. Effect of a cold exposure Arthritis Rheum. 46 2002 1319 1323
41. A. Barden, L.J. Beilin, J. Ritchie, K.D. Croft, B.N. Walters, and C.A. Michael Plasma and urinary 8-iso-prostane as an indicator of lipid peroxidation in pre-eclampsia and normal pregnancy Clin. Sci. (Colch) 91 1996 711 718
42. J.M. Morris, N.K. Gopaul, M.J. Endresen, M. Knight, E.A. Linton, and S. Dhir Circulating markers of oxidative stress are raised in normal pregnancy and pre-eclampsia Br. J. Obstet. Gynaecol. 105 1998 1195 1199
43. S.W. Walsh, J.E. Vaughan, Y. Wang, and L.J. Roberts 2nd Placental isoprostane is significantly increased in preeclampsia FASEB J. 14 2000 1289 1296
44. E.T. McKinney, R. Shouri, R.S. Hunt, R.A. Ahokas, and B.M. Sibai Plasma, urinary, and salivary 8-epi-prostaglandin F2a levels in normotensive and preeclamptic pregnancies Am. J. Obstet. Gynecol. 183 2000 874 877
45. C.M. Stein, S.B. Tanner, J.A. Awad, L.J. Roberts, and J.D. Morrow Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma Arthritis Rheum. 39 1996 1146 1150
46. J.L. Cracowski, C. Marpeau, P.H. Carpentier, B. Imbert, M. Hunt, and F. Stanke-Labesque Enhanced in vivo lipid peroxidation in scleroderma spectrum disorders Arthritis Rheum. 44 2001 1143 1148